Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Undifferentiated Pleomorphic Sarcoma (SiARa-UPS)

NCT05017103 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05017103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05017103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) - Undifferentiated Pleomorphic Sarcoma (SiARa-UPS)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
July 13, 2021
Completion date
February 20, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced undifferentiated pleomorphic sarcoma, metastatic undifferentiated pleomorphic sarcoma, recurrent undifferentiated pleomorphic sarcoma, unresectable undifferentiated pleomorphic sarcoma